Pacific Biosciences Of California (PACB) Cash from Investing Activities Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | 17.83% |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | -6.23% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | -24.52% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | -32.54% |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | -68.12% |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | 37.39% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | -11.04% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | 19.58% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | -17.67% |
| 10 | Pacific Biosciences Of California | 394.53 Mn | 157.66 Mn | 12.64 Mn | 34.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.01% |
| Mar 31, 2026 | 35.62% |
| Dec 31, 2025 | -31.34% |
| Sep 30, 2025 | -29.48% |
| Jun 30, 2025 | 34.25% |
| Mar 31, 2025 | 2.46% |
| Dec 31, 2024 | -3.96% |
| Jun 30, 2024 | 29.40% |
| Mar 31, 2024 | -83.49% |
| Dec 31, 2023 | 12.24% |
| Sep 30, 2023 | 79.75% |
| Jun 30, 2023 | -225.49% |
| Mar 31, 2023 | -10.12% |
| Dec 31, 2022 | 194.69% |
| Sep 30, 2022 | 39.97% |
| Jun 30, 2022 | -113.39% |
| Mar 31, 2022 | 3.45% |
| Dec 31, 2021 | 140.59% |
| Jun 30, 2021 | -241.42% |
| Mar 31, 2021 | 45.09% |